| Market Capitalization (Millions $) |
556 |
| Shares
Outstanding (Millions) |
66 |
| Employees |
246 |
| Revenues (TTM) (Millions $) |
317 |
| Net Income (TTM) (Millions $) |
9 |
| Cash Flow (TTM) (Millions $) |
6 |
| Capital Exp. (TTM) (Millions $) |
3 |
Business Description
Arvinas Inc. is a biotechnology company that is based in New Haven, Connecticut. The company specializes in the development of a unique technology called PROTACe or Proteolysis-Targeting Chimera. This involves designing and developing small-molecule drugs that can specifically degrade target proteins within cells. The technology has the potential to revolutionize the way we treat diseases, particularly in areas where there is a high unmet medical need.
Arvinas was founded in 2013 by Dr. Craig Crews, a prominent scientist in the field of protein degradation. The company has since grown to become a leading player in the biotech industry, with over 200 employees and an extensive research and development program.
The company's goal is to develop drugs for diseases that are currently difficult to treat or have no effective treatments available. This includes a focus on oncology, where Arvinas is developing drugs to target specific types of cancer. The company is also working on drugs for neurodegenerative diseases, cardiovascular disease, and certain viral infections.
One of the key advantages of Arvinas' PROTAC technology is its ability to target specific proteins within cells. This allows for a more precise and effective treatment approach, while minimizing side effects. The company is also working on developing drugs that can penetrate the blood-brain barrier, which will be critical in treating neurodegenerative diseases.
Arvinas has a pipeline of drugs in various stages of development. The company's lead drug candidate, ARV-110, is currently in a Phase 2 clinical trial for the treatment of prostate cancer. The company also has several other drugs in preclinical development, including drugs for breast cancer, ovarian cancer, and Alzheimer's disease.
In addition to its internal research and development efforts, Arvinas has established collaborations and partnerships with leading pharmaceutical companies. This includes a collaboration with Pfizer to develop drugs for oncology and a partnership with Genentech to develop PROTAC-based drugs for disease targets.
Overall, Arvinas Inc. is a cutting-edge biotech company with a mission to revolutionize the way we treat diseases. Its unique PROTAC technology has the potential to transform the biotech industry, and the company's extensive research and development efforts have positioned it as a leader in the field. With a strong pipeline of drugs in development and strategic partnerships with leading pharmaceutical companies, Arvinas is well-positioned for future success.
Company Address: 5 Science Park New Haven 6511 CT
Company Phone Number: 535-1456 Stock Exchange / Ticker: NASDAQ ARVN
|
8.01 %